FDA Delegated Authority Over Clinical Trial Registry and Results Data Bank
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Food and Drug Administration
[Docket No. FDA-2012-N-0012]
Office of the Commissioner of Food and Drugs; Delegation of Authority
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
Notice is hereby given that I have delegated to the Commissioner of Food and Drugs (the Commissioner) certain authority added to the Public Health Service Act by section 801 of Public Law 110-85, the Food and Drug Administration Amendments Act of 2007 (42 U.S.C. 282(j)), pertaining to the expansion of the Clinical Trial Registry and Results Data Bank described therein. Specifically, the Commissioner is delegated the following authority:
• Section 402(j)(5)(C)(ii) of the Public Health Service Act (42 U.S.C. 282(j)(5)(C)(ii)) --To determine that any clinical trial information was not submitted as required under 42 U.S.C. 282(j) or was submitted but is false or misleading in any particular and to notify the responsible party and give such party an opportunity to remedy non-compliance by submitting required revised clinical trial information not later than 30 days after such notification.
This authority may be redelegated. This delegation will be exercised in accordance with the Department of Health and Human Services’ applicable policies, procedures, guidelines, and regulations. 2 oc2012262
I ratify and affirm any actions taken by the Commissioner or her subordinates that involved the exercise of the authority delegated herein prior to the effective date of this delegation. This delegation is effective upon date of signature.
Date: September 5, 2012.
Kathleen Sebelius,
Secretary of Health and Human Services.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
